Expanding spectrum of prion diseases.
Level 5 - mechanism / opinion, no new human data
Narrative review detailing mechanistic concepts and historical evidence without original human data or systematic methods.
PubMed 32803268 · doi:10.1042/ETLS20200037
What was done
This narrative review summarizes the history of prion discovery, from scrapie transmission studies establishing resistance to nucleic acid modification to the discovery of the 209-amino-acid cellular prion protein (PrPC) and its conversion into infectious PrPSc. It synthesizes literature applying this conformational templating model to broader neurodegenerative diseases.
What was found
The abstract reports conceptual mechanisms rather than quantitative data: - The scrapie pathogen was identified as a 209-amino-acid host-encoded protein without nucleic acid components. - Infectious PrPSc adopts a beta-sheet-enriched conformation via templated conversion of alpha-helical PrPC. - Self-propagating protein conformations occur from yeast to humans. - Alzheimer's disease is described as a double-prion disorder involving both amyloid-beta and tau prions. - Alpha-synuclein prions are implicated as pathogenic drivers in Parkinson's disease, multiple system atrophy, and Lewy body dementia. No statistical results or numbers are provided in the abstract.
Why it matters
It outlines the framework that broadens prion biology from rare transmissible encephalopathies to the pathogenesis of major neurodegenerative disorders characterized by self-propagating misfolded proteins.
Limits
The record is a non-systematic narrative review providing no primary experimental data, clinical cohort metrics, or quantitative measures. Applying the prion label to Alzheimer's and Parkinson's diseases reflects mechanistic hypotheses regarding protein seeding rather than evidence of classical disease transmission in humans.
Cited by
- supports Beta-amyloid is a prion, along with PrPSc and alpha-synuclein.